ArticleJournal of cardiovascular imaging2026
Echocardiographic guidance in transcatheter tricuspid valve interventions.
Article in Journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Echocardiographic guidance plays a pivotal role in pre-procedural screening and intraprocedural guidance for transcatheter tricuspid valve interventions (TTVI). Pre-procedurally, comprehensive transesophageal echocardiography (TEE) is essential to understand the tricuspid regurgitation (TR) mechanism, quantify TR severity, tricuspid leaflet morphology, right ventricular function/size, and help determine transcatheter tricuspid edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) selection based on underlying tricuspid valve anatomy. Interprocedurally, the use of real-time three-dimensional transesophageal echocardiography (3D-TEE) together with fluoroscopy allows precise guidance of device steering, leaflet insertion, and deployment while minimizing complications, especially in technically challenging tricuspid valve anatomy. Post-device deployment echocardiography assists in the assessment of residual TR, paravalvular leak, transvalvular gradient, right ventricular function changes, and the occurrence of pericardial effusion. As device technologies and indications for TTVI continue to expand, high-quality echocardiographic protocols and expertise are central to optimizing patient selection, procedural safety, and long-term outcomes in transcatheter treatment of tricuspid valve regurgitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.